Clinical Trial Update: Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan [Phase 3]

View source ↗

Summary

Phase III study of D9421-C 9 mg for active Crohn's disease in Japan completed; results posted on 2016-10-31.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• D9421-C

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-10-31